Results 121 to 130 of about 2,202,442 (302)
A double‐edged sword: The complex interplay between engineered nanoparticles and platelets
Bioengineering & Translational MedicineNanoparticles (NP) play a crucial role in nanomedicine, serving as carriers for localized therapeutics to allow for precise drug delivery to specific disease sites and conditions.
Yathreb Asaad +4 more
doaj +1 more source
Western Hemisphere Drug Policy Commission [website]
, 2021 Website of the Western Hemisphere Drug Policy Commission (WHDPC), charged to "evaluate a range of US counternarcotics programs in the Americas and then make recommendations to improve them" -- including a recording and transcript of the group's hearing ...
United States. Western Hemisphere Drug Policy Commission.
core
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Correspondence from John W. Emeigh
, 1955 This is a letter from John W. Emeigh, Secretary of the National Rural Letter Carriers' Association, sent to Charles Conaway. Emeigh writes that he received the check Conaway sent and thanks Conway for his endorsement of the enactment H.R ...
Delaware Rural Letter Carriers Association
core +2 more sources
Modified PLGA Nanoparticles as drug carriers for CNS delivery
, 2007 Modified PLGA Nanoparticles as drug carriers for CNS ...
FORNI, Flavio +10 more
core
MITF maintains genome stability in nonmelanocyte lineages
Molecular Oncology, EarlyView.MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir +13 more
wiley +1 more source
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Molecular Oncology, EarlyView.Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq +8 more
wiley +1 more source
Molecular Oncology, EarlyView.Detecting circulating tumor cells (CTCs) in blood before surgery may help predict outcomes in patients with head and neck squamous cell carcinoma (HNSCC). Here, we show when combined with tumor size and lymph node involvement from routine imaging, CTC status identifies high‐risk patients with poorer survival—offering a simple, minimally invasive tool ...
Susanne Flach +9 more
wiley +1 more source
Advancements in Cell Membrane–Based Biomimetic Carriers for Antitumor Therapy
Zhongliu Fangzhi YanjiuDrug delivery technologies are crucial components in drug development, greatly enhancing drug bioavailability and therapeutic efficacy and reducing toxic side effects.
Jiahe WU +3 more
doaj +1 more source